Podcasts about head and neck

Could clinical hypnosis improve outcomes for patients? Find out with Sarah Partridge, Consultant in Clinical Oncology at Imperial Healthcare NHS Trust, London. In this episode, Jonathan and Partridge discuss how hypnosis can be harnessed in a clinical setting, how it can be normalised, and its impact managing side effects. Use the following timestamps to navigate our episode! (00:00)-Introduction (01:45)-Sarah's route to clinical oncology (04:22)-Discovering and implementing hypnosis as a tool (08:12)-Hypnosis in managing side effects (12:18)-Hypnosis in clinical scenarios (16:31)-Tranceform: The era of digital resources (21:00)-Normalising clinical hypnosis (24:51)-Hypnosis: A different form of dissociative state

Interview with Upstate researcher Hani Aiash, MD, PhD

April is head and neck cancer awareness month. Dr. G. E. Ghali with Willis Knighton Oral and Maxillofacial surgery shares common symptoms, risk factors, prevention steps, and treatment options related to head and neck cancers.

Dentists are on the front lines when it comes to spotting signs of oral cancer and other abnormalities in the head and neck region. Yet, despite its importance, oral cancer screening is often overlooked during routine dental visits. Not only are these screenings vital for patient health, but they also present an opportunity for dental practices to leverage patients' medical insurance for reimbursement. To tell us all about it is Kandra Sellers. Kandra is a RDH with over 25 years in the dental industry. She is an educator in the field of oral systemic health, as well as founder and CEO of TIPS Medical Billing. Thanks to our episode sponsors: GC America - https://www.gc.dental/ BISCO - https://www.bisco.com/

Mucosal melanoma is a rare and aggressive form of melanoma that arises from the mucous membrane. In this podcast, we focus on mucosal melanoma of the head and neck. Led by A/Prof Sydney Ch'ng, our multidisciplinary experts discuss how it differs from cutaneous melanoma, staging of mucosal melanoma, management of the disease and future treatments. The discussion concludes with a case study to summarise key learnings. This podcast is suitable for Plastic Surgeons, Surgical Oncologists, Dermatologists, Medical Oncologists, Pathologists, GPs, Nurses and other healthcare professionals. SPEAKERS A/Prof Sydney Ch'ng - Plastic & Reconstructive Surgeon and Head & Neck Surgeon, Melanoma Institute Australia | Associate Professor of Surgery, The University of Sydney Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney A/Prof Raewyn Campbell - Rhinologist and Anterior Skull Base Surgeon |Associate Professor, Macquarie University Dr Robert Rawson - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital Prof Angela Hong - Radiation Oncologist, Melanoma Institute Australia | Clinical Professor, The University of Sydney Please note that this podcast was accurate at the time of recording (March 2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA's Education Program is proudly supported through unrestricted educational grants from MSD, BMS and HEINE.

Quintin Pan, PhD, explores the surge of HPV+ related head and neck cancers sparking the need for innovative treatment solutions. About Quintin Pan, PhD Learn more about the University Hospitals Research & Education Institute Follow Us on Social:          

Please visit answersincme.com/PQD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in squamous cell carcinoma of the head and neck (SCCHN) discusses the clinical potential of antagonists of inhibitor of apoptosis proteins (IAPs) for unresected, locally advanced SCCHN. Upon completion of this activity, participants should be better able to: Identify the rationale for investigating the use of antagonists of inhibitor of apoptosis proteins (IAPs) in the treatment of unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN); Discuss the latest efficacy and safety data for emerging IAP antagonists for the treatment of unresected LA SCCHN; and Outline clinical considerations for future use of IAP antagonists in unresected LA SCCHN.

Head and neck cancers are on the rise, and doctors often know it's there, even if they can't see a tumor. This morning, we look at how oncologists decide between starting treatment, or searching for the cancer's source.

BUFFALO, NY- January 31, 2024 – A new #research paper was #published on the #cover of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 2, entitled, “Prognostic significance of senescence-related tumor microenvironment genes in head and neck squamous cell carcinoma.” The impact of the senescence related microenvironment on cancer prognosis and therapeutic response remains poorly understood. In this new study, researchers Young Chan Lee, Yonghyun Nam, Minjeong Kim, Su Il Kim, Jung-Woo Lee, Young-Gyu Eun, and Dokyoon Kim from Kyung Hee University, Kyung Hee University Hospital at Gangdong, and the University of Pennsylvania investigated the prognostic significance of senescence related tumor microenvironment genes (PSTGs) and their potential implications for immunotherapy response. Using the Cancer Genome Atlas- head and neck squamous cell carcinoma (HNSC) data, the researchers identified two subtypes based on the expression of PSTGs, acquired from tumor-associated senescence genes, tumor microenvironment (TME)-related genes, and immune-related genes, using consensus clustering. Using the LASSO, they constructed a risk model consisting of senescence related TME core genes (STCGs). The two subtypes exhibited significant differences in prognosis, genetic alterations, methylation patterns, and enriched pathways, and immune infiltration. “Our risk model stratified patients into high-risk and low-risk groups and validated in independent cohorts.” The high-risk group showed poorer prognosis and immune inactivation, suggesting reduced responsiveness to immunotherapy. Additionally, the team observed a significant enrichment of STCGs in stromal cells using single-cell RNA transcriptome data. Their findings highlight the importance of the senescence related TME in HNSC prognosis and response to immunotherapy. “This study contributes to a deeper understanding of the complex interplay between senescence and the TME, with potential implications for precision medicine and personalized treatment approaches in HNSC.” DOI - https://doi.org/10.18632/aging.205346 Corresponding authors - Young-Gyu Eun - ygeun@khu.ac.kr, and Dokyoon Kim - dokyoon.kim@pennmedicine.upenn.edu Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205346 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, cellular senescence, head and neck cancer, immunotherapy, microenvironment, single cell About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

Editor in Chief Cecelia E. Schmalbach, MD, MSc, is joined by Associate Editor Babak Givi, MD, and lead author Leila J. Mady MD, PhD, MPH, to discuss “Gender Differences Among Head and Neck Microvascular Reconstructive Surgeons,” which published in the November 2023 issue of Otolaryngology–Head and Neck Surgery.  The research used a survey that was sent to facial plastic and maxillofacial surgeons, in addition to microvascular surgeons, to gain a comprehensive understanding of what causes gender differences in the subspecialty. One takeaway of note was that there were no gender differences when it came to training and practice patterns. Another revealed gender differences when explaining changes in practice—for men, the reasons related to career advancement; for women, the reasons related to burnout, usually related to work-life balance and especially if they have children.

In this episode of The Luke Coutinho Show, join me for an insightful conversation with the Director of Surgical Oncology at Apollo Cancer Centres - Dr. Anil D'Cruz. With over 35 years of experience, he has also served as the Director of Tata Memorial Hospital and Chief of Head and Neck Services, globally impacting guidelines through his research in head and neck cancers.Discover the key to cancer prevention and more insights on:Dr. D'Cruz's  journey to becoming an oncologist The factors causing head and neck cancers, and mucosal squamous cell cancersThe carcinogenic effects of the combination of tobacco and alcohol use and the risks of passive smokingThe preventable factors in cancer from habits (tobacco, alcohol, vaping, areca nut or supari), infections (hepatitis, HPV) and obesityThe role of curcumin (found in turmeric), green tea, and a nutrient-rich diet in cancer careThe importance of natural foods over artificial supplements and the key to a positive attitude for longevityThe powerful impact of the placebo effectAnd much more…

Bimekizumab vs secukinumab - Selenium sulfide for hyperkeratosis - Do kids with UP need epipens? - Meyerson phenomenon - Head-and-neck LCH - Want to donate to the cause? Do so here! http://www.uofuhealth.org/dermasphere Check out our video content on YouTube: https://www.youtube.com/@dermaspherepodcast and VuMedi!: https://www.vumedi.com/channel/dermasphere/ The University of Utah's Dermatology ECHO: ⁠⁠https://physicians.utah.edu/echo/dermatology-primarycare - ⁠⁠Connect with us! - Web: ⁠https://dermaspherepodcast.com/⁠ - Twitter: @DermaspherePC - Instagram: dermaspherepodcast - Facebook: https://www.facebook.com/DermaspherePodcast/ - Check out Luke and Michelle's other podcast, SkinCast! ⁠https://healthcare.utah.edu/dermatology/skincast/⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our friends at: - ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge) - ⁠https://www.levelex.com/games/top-derm⁠ (A free dermatology game to learn more dermatology!)

Behind the Knife ABSITE 2024 – Brand new, up-to-date, high yield learning to help you DOMINATE the exam. Don't forget to check out our NEW ABSITE Podcast Companion Book available on Amazon: https://www.amazon.com/Behind-Knife-ABSITE-Podcast-Companion/dp/B0CLDQWZG3/ref=monarch_sidesheet Behind the Knife would like to sincerely thank Medtronic for sponsoring the entire 2024 ABSITE podcast series.  Medtronic has a rich history of supporting surgical education, and we couldn't be happier that they chose to partner with Behind the Knife.  Learn more at https://www.medtronic.com/ If you like the work that Behind the Knife is doing, please leave us a review wherever you listen to podcasts.   Visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  

Interview with Michael J. Brenner, MD, author of Liquid Biopsies for Head and Neck Cancers—Any Hope for Human Papillomavirus–Negative Disease? Hosted by Paul C. Bryson, MD, MBA. Related Content: Liquid Biopsies for Head and Neck Cancers—Any Hope for Human Papillomavirus–Negative Disease?

Interview with Michael J. Brenner, MD, author of Liquid Biopsies for Head and Neck Cancers—Any Hope for Human Papillomavirus–Negative Disease? Hosted by Paul C. Bryson, MD, MBA. Related Content: Liquid Biopsies for Head and Neck Cancers—Any Hope for Human Papillomavirus–Negative Disease?

In this episode of BackTable ENT, Dr. Tammara Watts, surgeon-scientist at Duke University, sits down with host Dr. Gopi Shah to discuss two exciting scholarship opportunities for medical students available through the American Head & Neck Society (AHNS). --- SHOW NOTES Fewer than 5% of practicing otolaryngologists identify as members of underrepresented minority groups (URM), and these scholarships directly address that disparity. Gopi and Tammara then transition to discussing the importance of diversity in otolaryngology more broadly. First, Tammara expounds on what is gained by having a workforce that includes individuals with diverse backgrounds and experiences. Through the Dr. Eddie Méndez Research Fellowship and the Myers' Family Summer Fellowship, AHNS provides unique opportunities for aspiring otolaryngologists who identify as URM to connect with future colleagues. The Research Fellowship provides $10,000 to a medical student interested in spending one year immersed in otolaryngology research. It is unique in that AHNS provides a list of mentors (with bio-sketches) that interested applicants can connect with to formulate a research plan before applying. The Myers' Family Summer Fellowship financially supports a rising MS2 or MS3 student to gain exposure in Head & Neck Surgery. Next, Tammara offers tips on cultivating successful mentor-mentee relationships, emphasizing that mentors enjoy supporting their future colleagues, and that it is easier to do so when the mentee takes initiative. Finally, Tammara shares her philosophy regarding DEI. Though otolaryngologic patients come from all walks of life, their surgeons can't always conceptualize how their experiences influence their care. By supporting URM students interested in ENT, she (along with her AHNS colleagues) are helping create a workforce that can better understand and heal. --- RESOURCES AHNS's Dr. Eddie Méndez Fellowship: https://www.ahns.info/dr-eddie-mendez-research-fellowship/ AHNS's Myers' Family Summer Fellowship in Otolaryngology: https://www.ahns.info/myers-summer-fellowship/ Dr. Tammara Watts MD, PhD's Duke University Profile: https://headnecksurgery.duke.edu/profile/tammara-lynn-watts

ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses. The theme of the 2023 ASCO Annual Meeting was “Partnering With Patients: The Cornerstone of Cancer Care and Research.” From June 2 to 6 in Chicago, Illinois, and online, cancer researchers and clinicians from around the world gathered to discuss the latest cancer research and how to ensure that all people receive the cancer care they need. In the Research Round Up series, members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field presented at the meeting and explain what it means for people with cancer. In today's episode, our guests will discuss new research in gynecologic cancers [2:06], multiple myeloma [9:15], and head and neck cancer [16:03]. First, Dr. Lan Coffman discusses new research in ovarian cancer, uterine cancer, and cervical cancer. Dr. Coffman is a physician-scientist and gynecologic oncologist at the Magee-Womens Research Institute and Foundation, and assistant professor in Hematology-Oncology at the University of Pittsburgh School of Medicine. She is also the 2023 Cancer.Net Associate Editor for Gynecologic Cancers. You can view Dr. Coffman's disclosures at Cancer.Net. Dr. Coffman: Hi, my name is Lan Coffman. I'm a physician-scientist at the University of Pittsburgh. I'm a medical oncologist that specializes in gynecologic cancers, and I'm happy to discuss research that was presented on gynecologic cancers at the 2023 ASCO Annual Meeting. I do have a relevant disclosure. I participated in one of the trials I'm going to discuss, a trial called MIRASOL. I was the site principal investigator at University of Pittsburgh. I think there were a lot of interesting studies to highlight, and I wanted to focus on studies involving ovary cancer, endometrial cancer, and cervix cancers as the main sites that we study in the gynecologic oncology world. So when we talk about ovary cancer, I think there was one really impactful study that was presented at ASCO this year, and it was called MIRASOL. And again, this is the study that I also participated in at our hospital at University of Pittsburgh. So it was a large study, so a randomized phase 3 study looking at a drug called mirvetuximab, which is an antibody-drug conjugate. So basically, it's an antibody against a protein that is expressed on ovarian cancer cells and the protein's called folate receptor-alpha. And that antibody basically carries a little poison. And so it's kind of like a Trojan horse. This antibody goes, finds that protein on the tumor cells, and then delivers that poison. And so this drug has been studied and actually was presented last year in a different trial called SORAYA, which showed that it had activity, meaning the drug helped to kill ovarian cancer cells, and actually led to the first approval of this drug in ovary cancer. So this trial was the confirmatory trial, so enrolling more patients to see, actually, is it better than standard-of-care chemotherapy? So this was in women with ovarian cancer that had come back and was platinum resistant, meaning the cancer started to grow within 6 months from the last platinum-based therapy. Women were eligible if they had high expression of this folate receptor-alpha, and they had to have a couple of prior lines of therapy. And then they were randomized, so kind of chosen out of a hat to either be treated with mirvetuximab or with investigator's choice chemotherapy. So one of the chemotherapies we'd use standardly. And so that would be something like taxol, or liposomal doxorubicin, or topotecan. And basically, this study was comparing how well does mirvetuximab work compared to chemotherapy. And importantly, it showed that it improved survival, both progression-free survival, so how long it took before the disease started to grow again, but probably more importantly, actually improved overall survival, so how long a woman lived. And actually changed overall survival from about 16 and a half months compared to 12 months with chemotherapy. And so this was really important and demonstrated that mirvetuximab does actually impact women with ovarian cancer and actually helps women live longer. And that's really hard to do in this setting. And the other nice thing about this trial was that not only did it work well, but there are actually lower side effects with it, and so less women actually had to discontinue their treatment, and they had less what we call adverse events, or basically bad things that had happened from the treatment themselves. So just telling us that this drug is actually well tolerated. Women feel well on it, even when their cancer is shrinking. So I think that was one of the most impactful studies in ovary cancer. Moving on to endometrial cancer. We recently had 2 studies, one called RUBY and one called GY018 that looked at using immunotherapy in combination with chemotherapy in endometrial cancer. And what was presented at ASCO was some follow-up from this RUBY trial, which was basically validating that this combination of adding immunotherapy actually helped. To give you a background, traditionally, women that have endometrial cancer that is advanced staged, meaning spread outside of the uterus itself or has come back, we treat it with chemotherapy. But this study added an immunotherapy called dostarlimab in combination with our standard chemotherapy and actually showed that women were living longer with this, at least in that progression-free survival. We're still waiting on final evaluation. But at ASCO, what they reported was another independent blinded review of the data to show that even when we're really carefully looking at this data, it looks like immunotherapy helps women with endometrial cancer live longer. They also presented quality-of-life data showing that women actually feel better with the addition of the immunotherapy. So I think this is practice changing. And again, this data has been coming out over the last year or so, but I do think this will change the way in which endometrial cancer is treated. And then the final thing I wanted to discuss would be in cervix cancer. And while there wasn't a lot of new data presented here in terms of kind of paradigm shifts or large changes, we did have final survival [data] from the KEYNOTE-826 presented, which is also using immunotherapy along with chemotherapy in cervix cancer. And so this was in women that, again, had advanced-stage cervix cancer. So it was a cervix cancer that had moved beyond the cervix itself or cervix cancer that had come back and was treated with chemotherapy along with another immunotherapy called pembrolizumab. And this was the final survival data that confirmed that the immunotherapy did help women live longer. The survival data was impressive with about a 10-month improvement in overall survival. So how long a woman lived. And so that was really confirmatory of the previous trials. So again, that emphasizes that immunotherapy is moved towards the standard of care in cervix cancer as well. I can't hit all the highlights of the impressive research coming out of ASCO 2023, this is a brief summary of some of the critical studies in gynecologic cancers. ASCO: Thank you, Dr. Coffman. Next, Dr. Sagar Lonial discusses new research in multiple myeloma. Dr. Lonial is a professor of Hematology and Medical Oncology at Winship Cancer Institute at Emory University, where he also serves as Department Chair. He is also the 2023 Cancer.Net Associate Editor for Myeloma. You can view Dr. Lonial's disclosures at Cancer.Net. Dr. Lonial: Hello, I'm Dr. Sagar Lonial from the Emory School of Medicine and the Winship Cancer Institute in Atlanta, Georgia. And today I'm going to discuss some of the really exciting research in the context of multiple myeloma that was presented at the 2023 ASCO Annual Meeting. In terms of my conflicts of interest, I have enrolled patients on many CAR T trials as well as bispecific trials from all of the different companies involved here. So, I do have some engagement with those trials. And one of the studies that I may talk about at the end came from our institution. So I was an investigator on that study as well. When I think about some of the really exciting work that was presented at ASCO this year, there are really 2 big categories of trials that I think were most exciting. And the first is CAR T-cells and moving them earlier and earlier in the disease state. And what we saw at ASCO this year was the CARTITUDE-4 study, which was a randomized phase 3 trial comparing CAR T-cells versus standard treatment in the context of first or second relapsed multiple myeloma. And this was a really important study for us to hear because we know that CAR T-cells are highly effective in the later lines of therapy. A big question at this point is, "Does their efficacy hold up in earlier lines of therapy? And how does it compare in a randomized setting against what we might normally use in that clinical context?" And what I think we were really excited to see at ASCO this year was that CAR T-cells appear to be superior to standard treatment in the context of that randomized phase 3 trial. Now, there were a few patients who were randomized to CAR T-cells who didn't get to the CAR T-cell infusion because their disease progressed in that interval. And that is a challenge that many of us deal with on a regular basis when we think about using a CAR T in a patient. But in general, the treatment was available for almost all patients. And the analysis of benefit as measured by a longer remission duration for the patients who received CAR T cells versus those who didn't was really done on what we call an intent to treat basis. And what that means is if you were randomized to the CAR T arm, even if you didn't get the CAR T, which again was a very small number of patients, you were still evaluated as if you got a CAR. And what I think that tells us is that even taking into account some of those patients who may not get there, there still was significant clinical benefit. And this is really important data for us to have insight into. We've seen this with cilta-cel in CARTITUDE-4. We'd seen similar kinds of findings in KarMMa using ide-cel as the CAR T-cell, although it does appear that the remission duration, at least when you're comparing across trials, appears to be a little bit longer for cilta-cel than what we've seen with ide-cel. But nonetheless, it suggests that even in the context of early relapse, there may be some benefit for CARs over standard therapy. Now, does this mean that CARs are going to replace standard therapy in terms of early relapse? I don't think we know the answer to that right now. I think there's a lot of information that we need to look at to really feel comfortable making that step. The other big set of data I think that we were all very excited about to see at ASCO this year were the T-cell engagers or the bispecifics. And what we saw from a number of different bispecifics was that the efficacy data looks like it continues to hold up. But what to me was really quite exciting was the idea that the T-cell engager could be highly effective even if a patient had seen prior BCMA-directed therapy. And what this means to me is that perhaps if you're progressing on a CAR T-cell, you still may have a pretty reasonable chance at a response, again, to a BCMA-directed therapy with a bispecific. The other way around may not necessarily be the same. And so I think what we learned at this meeting is that the bispecific or T-cell engagers clearly could have activity in the context of prior BCMA-exposed therapy. And I think, as a field, we need to think more about how we define what it means to be resistant to a BCMA-directed therapy. So that I think was really important and exciting and will have relevance in our daily clinical practice. We also saw updates on a different non-BCMA-directed target. So we saw updates on GPRC5D-targeted bispecifics, also known as talquetamab. What I think was really exciting here is we saw a very high overall response rate, modest infectious complications compared to what we've seen with BCMA-directed therapy.   Finally, what I want to wrap up with was a very small study addressing what I think is a pretty significant unmet medical need. And that was a trial from Dr. Nooka at my institution, where we evaluated a combination of carfilzomib with pomalidomide and dexamethasone, or KPD. And we used that specifically as maintenance in the high-risk group. And what we learned from that evaluation is that it appears for patients with high-risk disease that KPD maintenance is better than either carfilzomib and len [lenalidomide] or even bortezomib and lenalidomide, which historically has been what we're using. But there remains an unmet medical need patient population, particularly the double-hit patient population, that even with KPD still didn't have a great outcome overall. So more work for us to do down the road. But certainly, food for thought for many of those other patients that perhaps don't fit into that double-hit classic category. So I think what I've given you is a nice sort of overview of many of the exciting data that were presented at ASCO 2023. Again, go to the website to see additional ones. And thank you again for listening to this brief summary of research in myeloma updates from the 2023 ASCO Annual Meeting. ASCO: Thank you, Dr. Lonial. Finally, Dr. Cristina Rodriguez discusses new research in treating head and neck cancer. Dr. Rodriguez is a medical oncologist at Seattle Cancer Care Alliance, an Associate Professor in the Division of Medical Oncology at the University of Washington, and an Associate Member for solid tumor clinical research at the Fred Hutchinson Cancer Research Center. She is also the 2023 Cancer.Net Associate Editor for Head and Neck Cancers. You can view Dr. Rodriguez's disclosures at Cancer.Net. Dr. Rodriguez: Hello, my name is Cristina Rodriguez, and today I'm going to discuss some new research focusing on head and neck cancer that was presented at our annual ASCO 2023 meeting. As part of my disclosures, my institution receives research funding from CGEN. My takeaway from this meeting was there were a few major themes represented by the research. One of them was research on uncommon cancer types, such as nasopharyngeal cancer and salivary gland cancer. The other major theme and what was exciting for me was research on groups that were typically not represented in clinical trials in head and neck cancer. These include elderly or frail patients with many other comorbid illnesses that might have excluded them from clinical trials. Another theme was research in areas outside the developed world. In other words, resource-restricted countries. There was some exciting research coming out of that. And finally, a few new agents, novel agents that looked to have activity in patients with head and neck cancer that are going to be studied further. So with that, I'm going to start with talking about research that came out of France, presented by Dr. Fayette. This was a clinical trial that focused primarily on the frail elderly population. A group that might make very difficult for one to enter clinical trial because of many different illnesses or not being fit enough. And this group, out of France, looked at a combination of immunotherapy and a gentler lower dose chemotherapy called carboplatin and paclitaxel. Interestingly, in this group, there was very encouraging results, including 71% of patients having an objective response or a reduction in the size of their tumor, and very few patients, less than 5% of patients, having toxicity that required permanent discontinuation of the drug. So I thought this study was particularly interesting and gives us physicians and patients who are in this situation some more options to use when we're in the treatment of head and neck cancer. The next study that I thought was particularly interesting came out of India and was presented by Dr. Kothari. The special thing about this study was that it asked the question of the efficacy of a very low-cost combination for patients with recurrent or metastatic head and neck cancer. It's a combination that we don't tend to use here in the United States, one that involves methotrexate, celecoxib, and erlotinib. This particular clinical trial was carried out in several sites in India, and it randomized patients to this low-cost oral regimen versus physician's choice. In other words, any type of treatment that might involve immunotherapy or antibody therapy. The main issue here being that sometimes many of these therapies are not easily accessible to patients in low-resourced situations. The investigators observed an overall survival advantage, what that means is more patients lived longer when they use the low-cost oral regimen, which was much more practical, much easier for patients to take, and had more success in improving and prolonging the lives of patients. So I thought that that was a particularly important observation. And we forget a lot of times when we're practicing in the United States that a lot of our practice patterns here may not be applicable to low-resource settings. And I think it's very exciting that research is being carried out to answer questions that are relevant to this area. The third abstract that I thought was particularly intriguing was one presented by Dr. Glenn Hanna from Dana-Farber. And it looked at a new drug called BCA101. BCA101 is an antibody that has 2 functions. It inhibits EGFR, or epidermal growth factor receptor, very commonly overexpressed in head and neck squamous cell carcinomas. And it has a dual function, which is it modulates TGFβ, which is an immunosuppressive cytokine within tumor cells. This drug was combined with pembrolizumab in this small study and offered to patients who have never received treatment for recurrent or metastatic head and neck cancer. There was a lot of enthusiasm for this drug because in the 33 patients enrolled in the trial, 48% of them had an objective response, meaning a reduction in the size of their tumor. Anemia was one of the more common side effects that were noted. But the efficacy of this agent in this population, these patients expressed PD-L1 or had a CPS score of 1, was enough to support further study of this drug and a larger clinical trial is going to be carried out looking to see if this drug will have similar efficacy or better efficacy in a larger population. Finally, the last abstract is one that was presented by Dr. Swiecicki. And it was an interesting abstract to me because it examined the activity of another novel agent not FDA-approved for head and neck cancer, called enfortumab vedotin. This is a class of drugs that belong to a group called antibody-drug conjugates. This is an antibody that's directed toward the target called Nectin-4 and has a small chemotherapy payload that's attached to the antibody. Unlike Dr. Hanna's study, this study was a small phase 2 trial that focused on patients who've previously been treated in the recurrent or metastatic setting and are now receiving this drug either as their second or third option after they developed recurrent or metastatic disease. 46 patients were enrolled in this trial, and 24% of patients had an objective response or reduction in the size of this tumor. Although that number doesn't seem very high, it is an encouraging signal because in patients who previously received treatment for head and neck cancer, we tend to see very poor response rates. So this is encouraging given the population that was studied. Another 32% of these patients had what's called stable disease or no significant change in the size of their tumor. So that too is quite encouraging. This drug is going to also move on for further study in head and neck cancer. So I thought that these themes really brought about a lot of excitement for me for the future of treatments in patients with head and neck cancer, not only in developed countries but also in resource-restricted environments. And I look forward to next year and more work being done in these areas. And I'd like to thank you for listening to this brief summary of developments and head and neck cancer presented in the 2023 ASCO Annual Meeting. ASCO: Thank you, Dr. Rodriguez. You can find more research from recent scientific meetings at www.cancer.net. Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care. And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.

David I. Kutler, M.D. discusses what patients should now about head and neck cancers. He goes over the prevalence and causes of cancer, including smoking, drinking and HPV. He reviews how doctors can identify common symptoms, including checking for lumps and swollen lymph nodes. He also talks about the recent advancements in treatment, including reconstructive and robotics surgery and breakthroughs in immunotherapy. Finally, he highlights the importance of support and communication as part of multi-disciplinary care for patients.To schedule with David I. Kutler, M.D 

Guest: Heather Thompson, MS, CCC-SLP - In this one-hour audio podcast, Heather identifies how an SLP's role on the team leads to improved quality of life for people with head and neck cancer. Heather draws on her years of experience working on a multidisciplinary head and neck cancer team and research to provide evidence to support a multi-disciplinary approach throughout the continuum of care to facilitate quicker reintegration into the community.

ASMR Unboxing - ASMR Relaxing Head and Neck Massage Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

ASMR Victoria Magic Hands - Amazing ASMR Head and Neck Massage Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

ASMR head and neck massage for deep sleep Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Cat head and neck pruritus... what differentials for you have for a feline friend that is showing this pattern? Check out this week's episode of The Derm Vet podcast!Reference from the episode: Hobi S, et al. Clinical characteristics and causes of pruritus in cats: a multicenter study on feline hypersensitivity-associated dermatoses. Vet Dermatol 2011; 22: 406-413.

The epic journey of Josh and Michael across tumour streams at ASCO 2023 is approaching its end. It has been a whirlwind tour through groundbreaking science, hazard ratios and exciting glimpses into a brighter future for cancer patients. However, our intrepid duo's work is not yet done, merely reached its penultimate stage. In today's episode, Josh and Michael examine four notable studies in the spheres of melanoma and head and neck cancer. Spoiler alert: in this part of the map, here there be groundbreaking studies!StudiesFianlimab + cemiplimab: https://meetings.asco.org/abstracts-presentations/218502KEYNOTE-942: https://meetings.asco.org/abstracts-presentations/218505CONTINUUM: https://meetings.asco.org/abstracts-presentations/218513DEPEND: https://meetings.asco.org/abstracts-presentations/218516Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Please visit answersincme.com/EEF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in head and neck squamous cell carcinoma (HNSCC) discusses the clinical significance of emerging antagonists of inhibitors of apoptosis proteins (IAPs) for patients with HNSCC. Upon completion of this activity, participants should be better able to: Describe the biologic rationale for emerging antagonists of IAPs for patients with resectable and unresectable locally advanced (LA) HNSCC; Review the clinical significance of emerging antagonists of IAPs in the treatment of unresectable LA HNSCC, based on the latest efficacy and safety data; and Outline strategies for how antagonists of IAPs may fit into future treatment algorithms for patients with resectable and unresectable LA HNSCC, as they become available.

Military Medicine & WarDocs present: "A Ready Medical Force Special Collection" MILMED-D-22-00478R1: “An Analysis of Head and Neck Surgical Workload During Recent Combat Operations from 2002-2016” EPISODE SUMMARY Discover the critical insights from Dr. Caryn Stern and CDR Shane Jensen, MD on the prevalence of head and neck trauma cases managed by deployed surgeons during recent conflicts. This episode dives into their Military Medicine paper, which analyzes head and neck surgical workload at forward MTF's spanning 2 decades, and the importance of their findings for our military healthcare teams. Learn how this valuable information can be used to improve training and skill sustainment initiatives for future operations. We discuss the essential knowledge and skills that general surgeons need to have when deploying, such as those identified in the Individual Critical Task List (ICTL) and the Knowledge Skills and Abilities (KSA) project. We stress the importance of having an airway plan for facial fractures, securing an airway for mid-phase instability, and using external fixation for most fractures. We also explore what medics can be trained to do in head and neck injuries requiring a tracheostomy or lateral canthotomy, and the goal of getting life-saving treatment within an hour. Lastly, we examine the need for specialized teams of head and neck surgeons and the equipment they require to provide comprehensive support to Role 3 Military Treatment Facilities. We discuss the challenges of providing this specialized care, including the need for rapid telehealth support and feedback to those at Roles 1 and 2 MTFs. Don't miss this fascinating episode as we analyze the next steps needed to improve the training and equipping of units for managing head and neck trauma, and the importance of data collection and documentation in making informed decisions.   EPISODE CHAPTERS (0:00:01) – Trauma Data Collection in Recent Conflicts (0:13:34) - Combat Medical Procedures and Training (0:19:18) - Head & Neck Trauma Care in Combat (0:29:31) – Improving Head & Neck Trauma Care   EPISODE CHAPTER SUMMARIES (0:00:01) - Trauma Data Collection in Recent Conflicts We explore the prevalence of head and neck trauma cases managed by deployed surgeons during recent conflicts and how this information can be used to improve training and skill sustainment initiatives for future operations. The authors describe how they gathered data from the Department of Defense Trauma Registry, and how they divided the procedures into five groups: dental, ophthalmologic, airway, ear, face, mandible maxilla, neck, and oral. They discuss how these injuries are prevalent in theater and the importance of their findings. (0:13:34) - Combat Medical Procedures and Training (6 Minutes) We discuss the knowledge and skills that general surgeons need to have when deploying, such as the tasks identified in the Individual Critical Task List (ICTL) and the Knowledge Skills and Abilities (KSA) project. We bring up the importance of having an airway plan for facial fractures, securing an airway for mid-phase instability, and using external fixation for most fractures. We also touch on the goal of getting life-saving treatment within an hour and explore what medics can be trained to do in head and neck injuries requiring a tracheostomy or lateral canthotomy. (0:19:18) - Head & Neck Trauma Care in Combat (10 Minutes) We look at the need for specialized teams of head and neck surgeons and the equipment they require in order to provide comprehensive support to Role 3 MTFs. We discuss the challenges of providing this specialized care, including the need for rapid telehealth support and feedback to those at Role 1 and 2 MTFs. We then focus on the importance of data collection and documentation and the impact this has on the ability of epidemiologists to access the data needed to make informed decisions. Finally, we analyze the next steps needed to improve the training and equipping of units for managing head and neck trauma. (0:29:31) - Improving Head & Neck Trauma Care We discuss the importance of medical evacuation teams and their role in providing care to injured service members. We examine the impact of recent conflicts on the availability of resources for head and neck trauma cases and how this has necessitated the use of specialized teams and equipment. We also look at the training requirements for medical evacuation teams and the need for increased coordination between different branches of the military.   EPISODE KEYWORDS Head & Neck Trauma, Military Medicine, Deployed Surgeons, Individual Critical Task List, Knowledge Skills & Abilities, Airway Plan, Mid-Phase Instability, External Fixation, Tracheostomy, Specialized Teams, Telehealth Support, Data Collection, Documentation, Medical Evacuation Teams, Training Requirements, Coordination, Military Branches   #Military #Medical #Podcast #WarDocs #HeadandNeckTrauma #SurgicalTeams #ICTLS #KSAs #MilitaryMedicine #Telemedicine #Training #AustereEnvironments #JointTraumaSystem #JTS   Honoring the Legacy and Preserving the History of Military Medicine The WarDocs Mission is to improve military and civilian healthcare and foster patriotism by honoring the legacy, preserving the oral history, and showcasing military medicine career opportunities, experiences, and achievements. Find out more and join Team WarDocs at https://www.wardocspodcast.com/ Check our list of previous guest episodes at https://www.wardocspodcast.com/episodes  Listen to the “What We Are For” Episode 47. https://bit.ly/3r87Afm WarDocs- The Military Medicine Podcast is a Non-Profit, Tax-exempt-501(c)(3) Veteran Run Organization run by volunteers. All donations are tax-deductible, and 100% of donations go to honoring and preserving the history, experiences, successes, and lessons learned in military medicine. A tax receipt will be sent to you. WARDOCS documents the experiences, contributions, and innovations of all military medicine Services, ranks, and Corps who are affectionately called "Docs" as a sign of respect, trust, and confidence on and off the battlefield, demonstrating dedication to the medical care of fellow comrades in arms.           Follow Us on Social Media Twitter: @wardocspodcast Facebook: WarDocs Podcast Instagram: @wardocspodcast LinkedIn: WarDocs-The Military Medicine Podcast

Emrullah Yilmaz, MD, PhD, an oncologist at Cleveland Clinic Taussig Cancer Institute specializing in head and neck cancers, joins the Cancer Advances podcast to discuss new ASCO guidelines for recurrent and metastatic head and neck cancers. Listen as Dr. Yilmaz explains how the guidelines focus on biomarkers, tumor mutation burdens, and how they will impact patient care.

The palm is ~0.5% TBSA - Insurance companies denying coverage - Malignancy risk in JAK inhibitors - MACE risk in JAK inhibitors - Oral azoles for head-and-neck dermatitis - Luke's PDPC course and the Intermountain Derm Society meeting: https://registration.socio.events/e/idspdpc23/promo-codes/ATTENDEE Connect with us! - Web: https://dermaspherepodcast.com/ - Twitter: @DermaspherePC - Instagram: dermaspherepodcast - Facebook: https://www.facebook.com/DermaspherePodcast/ - Check out Luke and Michelle's other podcast, SkinCast! https://healthcare.utah.edu/dermatology/skincast/ Luke and Michelle report no significant conflicts of interest… BUT check out our friends at: - Kikoxp.com(a social platform for doctors to share knowledge) - https://www.levelex.com/games/top-derm (A free dermatology game to learn more dermatology!)

John Papastergiou, BScPhm, PhDc - Human Papillomavirus Head and Neck Cancers: Improving Outcomes in Adults Through Vaccination

Gordon Elder DCCJP At the time of the recording (September 2022), Dr. Elder ha just finished a three-year program that, because of COVID, ended up being a four-year program. It was a 300-hour program for a post-doctorate degree in health for the brainstem, the craniocervical junction. The title is Diplomate. It's a DCCJP, Diplomate in Chiropractic Craniocervical Junction Procedures.The course was divided up into 12-hour weekends that were held in several different cities. They ran all day Saturday and half the day on Sunday, usually once a month for nine months of the year. It's a post-doctorate degree. A chiropractor can't call themself a specialist in anything unless they have a Diplomate in an approved program. The beginning was a basic deep-dive, then it moved on to remind you what you had learned in school and more. Then on to the limits of research and current research.The brainstem is the first thing that starts working at conception, that's the first part that's formed and it's the last part that stops working when you die. It's based at the base of the skull and the top of the neck. You cannot be alive if your brainstem is not functional.Dr. Elder likes to work together with other specialists to resolve complicated cases, as opposed to just hoping that what he does eventually works. He says this about the DCCJP community, “ What I've noticed here is when you get people who are super dedicated to advancing, you realize how much you know and how much you don't know. How much somebody else may be-- what knowledge they may have. You don't have the time, background, or expertise to become experts in every field. You're happy to refer out and work together with other specialists and true specialists, not just somebody else who knows a little something. Really work together with other specialists to resolve the complicated cases instead of just hoping that what you do eventually works.”Excel Still More. Dr. Elder plans to continue learning and doing some research now that he has time. He says about the Diplomate, “ It's given me the knife and the fork and told me where the food is, and now I can go get the food and start working on it.”To contact Ruth, go to https://www.blairclinic.comruth@blairclinic.comhttps://www.facebook.com/rutelin

This week's episode will be focusing on head & neck cancers. We will go over high yield testable facts on the epidemiology, diagnosis, staging and treatment of head & neck cancers.

Dr. Emrullah Yilmaz reviews the latest evidence and recommendations for health care providers on biomarker testing and immunotherapy for head and neck cancers. He discusses the ASCO Expert Panel's recommendations for biomarkers for the selection of patients with head and neck squamous cell carcinoma for anti-PD-1 immune checkpoint inhibitor therapy. Additionally, he reviews recommended treatment options, including first-line treatment based on PD-L1 status, therapies for platinum-refractory disease, options for patients with nasopharyngeal cancer, the role of radiation therapy for oligometastatic head and neck cancer, and immunotherapy for rare head and neck cancers. Dr. Yilmaz also explores future areas of research for therapeutic options for patients with head and neck squamous cell carcinoma. Read the full guideline, “Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline” at www.asco.org/head-neck-cancer-guidelines. TRANSCRIPT Brittany Harvey: Hello, and welcome to the ASCO Guidelines podcast series, brought to you by the ASCO Podcast Network; a collection of nine programs, covering a range of educational and scientific content and offering enriching insight into the world of cancer care. You can find all the shows, including this one, at: asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Emrullah Yilmaz, from Cleveland Clinic in Cleveland, Ohio, lead author on, 'Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline'. Thank you for being here today, Dr. Yilmaz. Dr. Emrullah Yilmaz: Thank you so much. Brittany Harvey: Then first, I'd like to note that ASCO takes great care in the development of its guidelines, and ensuring that the ASCO Conflict of Interest policy is followed for each guideline. The full conflict of interest information for this guideline panel is available online with the publication of the guideline in the Journal of Clinical Oncology. Dr. Yilmaz, do you have any relevant disclosures that are directed related to this guideline topic? Dr. Emrullah Yilmaz: No, I don't have a relevant disclosure. Brittany Harvey: Thank you. Then let's dive right into this guideline. So, generally, what is the purpose and the scope of this guideline? Dr. Emrullah Yilmaz: Immunotherapy with anti-PD-1 immune checkpoint inhibitors has become one of the most important treatment options for patients with recurrent metastatic head and neck cancers. And in the last few years, there has been new studies leading to new indications such as combinations with chemotherapy, or single-agent immunotherapy in the first-line treatment. And moreover, several studies also shown the effectiveness of immunotherapy for patients with nasopharyngeal carcinoma. All these advances in this complex disease group made it necessary to have an evidence-based guideline. So, that was the basis of building this guideline. Brittany Harvey: Understood. And then this evidence-based guideline addresses six clinical questions. So, I'd like to review the key recommendations for each of those questions for our listeners. So, let's start with the first question. What did the expert panel recommend regarding biomarkers for selecting patients with head and neck squamous cell carcinoma for anti-PD-1 immune checkpoint inhibitor therapy? Dr. Emrullah Yilmaz: Biomarkers are key for selection of treatment for immunotherapies, especially for the first-line treatment for head and neck cancer patients. PD-L1 is measured by immunohistochemistry and reported as Combined Positive Score, CPS, or Tumor Proportion Score, TPS. CPS is slightly different than TPS, and it includes lymphocyte and macrophage PD-L1 expression, in addition to tumor cells. Head and neck cancer studies have shown that CPS is a better marker for predicting response to immune checkpoint inhibitors, and key head and neck trials started to use CPS for reporting PD-L1 status. Therefore, we recommend CPS for recurrent metastatic head and neck cancers for PD-L1 reporting. This also makes it important for the oncologists to have a communication with the pathologists to make sure the right PD-L1 scoring is reported for head and neck cancer patients. Tissue tumor mutation burden is another emerging biomarker when CPS is not available, or for rare head and neck tumors, tumor mutation burden can be used as a biomarker as well. Brittany Harvey: Great. And then based on that PD-L1 status that you just mentioned, what is the optimal first-line treatment regimen for patients with recurrent or metastatic head and neck squamous cell carcinoma? Dr. Emrullah Yilmaz: If PD-L1 is positive, which is CPS more than one, there are two different options. Both pembrolizumab, single agent or pembrolizumab plus chemotherapy with platinum and 5-Fluorouracil can be offered. KEYNOTE-048 study showed an overall survival benefit with pembrolizumab alone for patients with CPS more than one, which was greater for the patients with CPS 20 or more. However, the pembrolizumab plus chemotherapy has showed benefit for the patients regardless of the PD-L1 status. So, if an early response is needed for a patient with high disease burden, pembrolizumab with chemotherapy could be an option, even if the PD-L1 is positive. For patients with negative PD-L1, which is CPS less than one, we recommend pembrolizumab and chemotherapy. There was a recent subgroup analysis of KEYNOTE-048 for CPS-low patients. Patients with CPS less than one subgroup did not have significant survival difference with pembrolizumab plus chemotherapy when compared to cetuximab plus chemotherapy. This included a small number of patients, and this study was not powered to look at this subgroup, but cetuximab and chemotherapy can also be considered in the PD-L1 negative patient. Brittany Harvey: Understood. It's important to recognize which patients benefit from these treatments more than others in different subgroups. So, following that, what is the effect of immunotherapy compared to other systemic treatments in platinum-refractory recurrent, or metastatic head and neck squamous cell carcinoma? Dr. Emrullah Yilmaz: Platinum-refractory disease is defined as recurrence within six months of platinum-based chemotherapy. And effectiveness of immunotherapy was actually proven in this disease group first, several years ago. The effectiveness of immunotherapy as a single agent was proven in two similarly designed phase III trials in this setting. CheckMate 141 trial compared nivolumab to standard-of-care methotrexate, cetuximab, or docetaxel, and KEYNOTE-040 trial compared pembrolizumab to similar standard-of-care agents. And both studies showed overall survival benefit when compared to standard-of-care systemic agents, and the responses were independent from the PD-L1 expressions. So, nivolumab or pembrolizumab, are options as single-agent immunotherapy treatments for the patients with platinum-refractory head and neck squamous cell carcinoma, regardless of their PD-L1 expression. Brittany Harvey: Understood, and thank you for getting into those options for those patients. Getting into the specifics for nasopharyngeal carcinoma, what did the panel recommend regarding the role of immunotherapy for patients with recurrent or metastatic nasopharyngeal carcinoma? Dr. Emrullah Yilmaz: So, the combination of immunotherapy with cisplatin and gemcitabine was shown to be effective in first-line treatment of recurrent metastatic nasopharyngeal carcinoma, in several phase III studies from Asia in the last few years. JUPITER-02 study used toripalimab, CAPTAIN-1 study used camrelizumab, and RATIONALE-309 study used tislelizumab in combination with cisplatin and gemcitabine in the first-line treatment, and all these studies showed progression-free survival benefit with addition of immunotherapy to chemotherapy. Since these agents are not available in the United States as of now, our panel members recommend that pembrolizumab or nivolumab may be offered in combination with chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. But the role of immunotherapy in the platinum-refractory nasopharyngeal carcinoma without the prior immunotherapy use is not well established yet. There are phase II studies that have shown that responses to immunotherapy are comparable to chemotherapy with a better safety profile. So, single-agent immunotherapy could be considered in a platinum-refractory setting if a PD-1 inhibitor was not used before. Brittany Harvey: Those are excellent points that you just made. So, following that, the next question that the panel considered is, what is recommended regarding the use of radiation therapy in combination with immunotherapy versus immunotherapy alone, for the treatment of locoregionally recurrent or oligometastatic head and neck squamous cell carcinoma? Dr. Emrullah Yilmaz: This is a great question, and radiation therapy is used a lot in head and neck cancers for different purposes. And immunotherapy and SBRT combinations were not shown to increase efficacy for abscopal effect for the treatment of oligometastatic disease in head and neck cancers. So, radiation therapy should not be given to increase the effectiveness of immunotherapy in recurrent metastatic head and neck cancers. However, there are several ongoing studies to evaluate the efficacy of radiation such as SBRT with immunotherapy for locoregional recurrence. So, although radiation therapy is safe to give the patients with recurrent and metastatic cancers, with immunotherapy, it should be considered for palliation or local control until the results of these trials are available. Brittany Harvey: Great. And yes, we'll look forward to the results of those trials to find some more definitive results for these patients. So, then, the last clinical question that the panel addressed, what is recommended for the role of immunotherapy for rare head and neck cancers? Dr. Emrullah Yilmaz: The role of the immunotherapy for rare head and neck cancers depends on the biomarkers. KEYNOTE-158 study has shown the effectiveness of pembrolizumab in advanced cancer patients, which included different types of cancers with high tissue TMB defined as more than 10 mutations per megabase. And looking at the results from that study for the patients with advanced rare head and neck cancers with limited treatment options, such as, salivary gland cancers or sinonasal cancers, if high TMB, which is Tumor Mutational Burden, is identified, then pembrolizumab may be considered for those patients. And pembrolizumab was also shown to have activity in salivary gland cancer patients expressing more than 1% PD-L1. So, that makes it an option for these patients as well. Brittany Harvey: It sounds like understanding the biomarker status of these patients with rare head and neck cancers is essential for determining their therapy options. I want to thank you so much for reviewing all of those recommendations. So, in your view, Dr. Yilmaz, what is the importance of this guideline, and how will it impact clinicians and patients with head and neck squamous cell carcinoma? Dr. Emrullah Yilmaz: This guideline was written by panel members, experts in their field, including medical oncologists, radiation oncologists, head and neck surgeons, pathologists, and radiologists. It is really important for oncologists to communicate the treatment options to their patients clearly while planning treatment of head and neck cancers. So, this guideline can help the clinicians to provide evidence-based resource when to use the immunotherapy for their head and neck cancer patients. So, that can be really helpful to the clinicians. Brittany Harvey: Excellent. Yes, it's important to have a multidisciplinary group working on these guidelines to help clinicians in all capacities. Finally, what outstanding questions or ongoing research are you interested in for future therapeutic options in head and neck squamous cell carcinoma? Dr. Emrullah Yilmaz: Our guideline focuses on recurrent metastatic head and neck cancers since it is the only area where the immunotherapy is approved as of now. We've had a few studies in the curative intent setting, which has not shown the benefit of addition of immunotherapy to radiation therapy, or chemoradiation. There's still several studies ongoing to investigate the effectiveness of immunotherapy in the curative intent setting, and the neoadjuvant setting, or adjuvant setting, or different combinations with the radiation therapy, with the immunotherapy, with the different sequences. So, it will be interesting to see the results of those studies in the future. So, that might be another area that the field might be moving in the future. There are also studies ongoing to improve effectiveness of the immunotherapy in the recurrent and metastatic disease. Chemoimmunotherapy seems to be among the strongest systemic treatment options right now that we have, but there are several other combination strategies that are being developed combined with the PD-1 inhibitors, including combinations with EGFR inhibitors, angiogenesis inhibitors, intratumoral injections, vaccine developments, and there are a lot of different novel checkpoint inhibitors being developed. So, the field is advancing in that area as well. So, those are the areas that research are ongoing at this point. Brittany Harvey: Definitely. We'll look forward to the results of those ongoing trials to inform future updates and future guidelines in this area. So, I want to thank you so much for all of your work that you put into developing these evidence-based guidelines and thank you for your time today, Dr. Yilmaz. Dr. Emrullah Yilmaz: Thank you so much. Brittany Harvey: And thank you to all of our listeners for tuning to the ASCO Guidelines podcast series. To read the full guideline, go to: www.asco.org/head-neck-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, available in iTunes or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast, and be sure to subscribe, so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy, should not be construed as an ASCO endorsement.  

This episode features Kyle Underwood, Program Manager, Head and Neck Institute at Cleveland Clinic, & Adam Haas, Administrative Assistant, Head and Neck Institute at The Cleveland Clinic. Here, they share advice for young professionals looking to get into healthcare administration. 

Deadly fungus!   This can kill a patient fast.   Can you recognize the imaging features in time?  In this week's podcast, Dr. Ross Frederick summarizes a very important paper on Invasive Fungal Sinusitis- don't miss this one! Deadly Fungi: Invasive Fungal Rhinosinusitis in the Head and Neck. Kurokawa and Kurokawa et al. RadioGraphics 2022; 42:2075–2094.  

A new research paper was published in Oncotarget's Volume 13 on October 20, 2022, entitled, “Nectin-4 is widely expressed in head and neck squamous cell carcinoma.” Nectin-4 has been successfully established as a target molecule in locally advanced and metastatic bladder cancer. An antibody-drug conjugate (enfortumab-vedotin) directed against nectin-4 has shown marked tumor remission rates in this tumor type, which is known for high expression rates of nectin-4. As head and neck cancer and urothelial carcinomas share morphological and molecular similarities, researchers Christine Sanders, Jan-Frederic Lau, Dimo Dietrich, Sebastian Strieth, Peter Brossart, and Glen Kristiansen from University Medical Center Bonn and University Hospital Bonn aimed to evaluate Nectin-4 expression in head and neck squamous cell carcinoma (HNSCC). A previously described and clinically characterized cohort of HNSCC (n = 159) was analyzed by immunohistochemistry for Nectin-4 expression. The expression data was correlated to clinico-pathological parameters including patient outcome. Nectin-4 was found in 86.2% of HNSCC, with medium/high expression seen in 32.7% of cases. Non smokers and p16 positive HNSCC showed a higher expression of Nectin-4 (p < 0.005). There was no correlation of Nectin-4 with grading or tumor stage. Nectin-4 positive tumors showed significantly better survival (log rank p = 0.006). “Similar to urothelial carcinoma, Nectin-4 is found in the majority of HNSCC, which clearly warrants further studies to clarify if HNSCC also respond to targeted therapy with enfortumab-vedotin. Moreover, expression of Nectin-4 is associated with HPV infection and may serve as a prognostic marker in HNSCC.” DOI: https://doi.org/10.18632/oncotarget.28299 Correspondence to: Glen Kristiansen - Email: glen.kristiansen@ukbonn.de Video - https://www.youtube.com/watch?v=tDY21YpFsKc Keywords: Nectin-4, enfortumab-vedotin, HNSCC, p16 About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media: Twitter – https://twitter.com/Oncotarget Facebook – https://www.facebook.com/Oncotarget YouTube – www.youtube.com/c/OncotargetYouTube Instagram – https://www.instagram.com/oncotargetjrnl/ LinkedIn – https://www.linkedin.com/company/oncotarget/ Pinterest – https://www.pinterest.com/oncotarget/ LabTube – https://www.labtube.tv/channel/MTY5OA SoundCloud – https://soundcloud.com/oncotarget For media inquiries, please contact: media@impactjournals.com Oncotarget Journal Office 6666 East Quaker Str., Suite 1A Orchard Park, NY 14127 Phone: 1-800-922-0957 (option 2)

Rates of thyroid cancer in adults and children have seen a steep increase over the past decade, making it the fastest-rising cancer in the U.S. Rachel Georgopoulos, MD, pediatric otolaryngologist and Director of the Thyroid Head and Neck Oncology and Pediatric Endocrine Center (Thyroid HOPE), joins to discuss the innovative research and treatment happening at Cleveland Clinic Children's.

Featuring perspectives from Dr Robert Haddad, including the following topics: ESMO 2022 (0:00) Case: A man in his early 50s presents with metastatic anaplastic thyroid cancer — Ezra Cohen, MD (18:39) Case: A man in his late 60s who has undergone immunotherapy for melanoma is diagnosed with Stage I (cN2 N1) p16-positive squamous cell carcinoma (SCC) of the left tonsil — Erik Rupard, MD (26:21) Case: An Asian woman in her early 40s who has received cisplatin/radiation therapy and gemcitabine/cisplatin for locoregionally advanced nasopharyngeal cancer develops metastatic disease (PD-L1 CPS 10) — Dr Cohen (31:21) Case: A man in his early 70s presents with recurrent and rapidly progressing HPV-negative metastatic head and neck cancer — Neil Morganstein, MD (38:55) Case: A man in his late 50s who has undergone definitive radiation therapy and surgery for locally recurrent SCC of the head and neck presents with worsening shortness of breath — Mamta Choksi, MD (41:42) Case: A man in his early 70s with a longstanding history of T-cell large granular lymphocytic leukemia presents with metastatic HPV-positive SCC of the left nostril (PD-L1-negative) — Spencer H Bachow, MD (44:50) Case: A man in his late 50s presents with HPV-positive Stage III cancer of the base of the tongue — Dr Cohen (49:03) Case: A man in his early 70s presents with metastatic anaplastic thyroid cancer (PD-L1-positive, mutations in TERT promoter, PT53 and MEN1) — Dr Rupard (52:00) Case: A man in his early 60s presents with metastatic papillary thyroid cancer with a BRAF V600E mutation — Dr Cohen (56:16) CME information and select publications

Featuring a discussion on the treatment of head and neck and thyroid cancers with Dr Robert Haddad, moderated by Dr Neil Love.

Laura Rutledge and the NFL Live Crew discuss Mike McDaniel's comments on Tua's head and neck injury, John Harbaugh's reaction to Tua's injury and Doug Pederson's return to Philly this weekend. Learn more about your ad choices. Visit megaphone.fm/adchoices

Robert Mays and Mike Jones discuss Tua Tagovailoa's head and neck injuries and, more importantly, the process that allowed him to take the field in the first place. Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome to the Head and Neck Innovations Podcast. Hosted by Dr. Paul Bryson, Director of the Cleveland Clinic Voice Center in our Head & Neck Institute, our podcast for medical professionals explores the latest innovations, discoveries, and surgical advances in Otolaryngology – Head and Neck Surgery. In our first episode, we're joined by Dr. Sarah Sydlowski, Associate Chief Improvement Officer and Audiology Director of Cleveland Clinic's Hearing Implant Program and current President of the American Academy of Audiology. Dr. Sydlowski discusses new eye-opening research into hearing health perceptions and candidacy criteria.

Luke learns about truck motors and shares a couple stories about tipped over end dumps and head and neck anatomy. Jaxon touches on speed limiters and why he thinks it may not be such a great idea.

Vascular malformations in the face are lesions with potential psychosocial and functional consequences to the patient. Jesse Jones, MD—an interventional neuroradiologist—and Anthony Morlandt, MD, DDS, FACS—an  oral and maxillofacial surgeon—discuss their interdisciplinary approach to diagnosing and treating these complex lesions. They highlight the importance of accounting for and controlling blood flow in a vascular malformation during surgery to preserve facial function and appearance.

Dr. Evan Walgama is a Head & Neck Oncology Surgeon, which means that he specializes in treating any cancer affecting areas from the collar bone to the base of the brain. While in the past, head and neck cancer surgeons tended to see older patients in poorer health who were often smokers coming in for treatment, the demographics have shifted. Dr. Walgama's practice is following this national trend, where younger, healthier, non-smokers, and often male patients are filling his waiting room.The culprit is HPV – human papillomavirus. Patients may develop tumors in the mouth, tongue, throat, or skull base for other reasons as well. Surgery is sometimes a good option, and in other cases, chemotherapy and radiation might be considered better. Shared decision making with his patients is something Dr. Walgama advocates for. “I'm a surgeon, but not everybody needs surgery,” Dr. Walgama says. Listen to this podcast to learn how Dr. Walgama deals with tricky tumors in a delicate region of the body

This episode features Dr. Ofer Azoulay. He serves as  Assistant Professor and Chief of Robotic and Microvascular Head and Neck Reconstruction at SUNY Downstate Health Sciences University. Be sure to check out the Downstate ENT Patient Stories we discuss in this week's episode: Matthew Racies: https://www.youtube.com/watch?v=dwYra708wF4&ab_channel=DownstateTV John Rodriguez: https://www.youtube.com/watch?v=aV3BLG_eZOw&ab_channel=DownstateTV Natalia Plaza: https://www.youtube.com/watch?v=Os5zRSVRQW0&ab_channel=DownstateTV Mary Williams: https://www.youtube.com/watch?v=8q_FYXrdCSQ&ab_channel=DownstateTV 

Dr. Shah Islam MBBS BSC (Hons) FRCR interviews Edward P. Lin, MD, MBA on his recent paper titled: Head and Neck Paragangliomas: Updated Classification, Imaging, and Management Recommendations Head and Neck Paragangliomas: An Update on the Molecular Classification, State-of-the-Art Imaging, and Management Recommendations. Lin et al. Radiology: Imaging Cancer 2022; 4(3):e210088. 

Tim Ryan (info @ stronglifetraining.com) is the owner of Strong Life Personal Training in Barrington, Illinois. He is a Master Super Slow instructor with certifications from ACSM, ACE, and the Super Slow Exercise Guild. His expertise includes personal training, mentoring trainers, and exercise equipment design.  Contact Tim for his business services here: Website: stronglifetraining.com Email: info @ stronglifetraining.com Phone (US): 630-862-5176 Listen to Part 1-5: 352 – Tim Ryan – The History and Philosophy of HIT – The High Intensity Training Fundamentals Series 354 – Tim Ryan – How to Articulate the Benefits of HIT – The High Intensity Training Fundamentals Series – Part 2 358 – Tim Ryan – Movement Speed – The High Intensity Training Fundamentals Series – Part 3 360 – Tim Ryan – The Optimal Window for Time Under Load and Time To Concentric Failure – The High Intensity Training Fundamentals Series – Part 4 361 – Tim Ryan – How to Determine the Optimal Resistance Level – The High Intensity Training Fundamentals Series – Part 5  In this episode, Tim joins me for Part 6 of our HIT Fundamentals Series where he discusses the assumed vs. real objective of exercise, common form discrepancies, how to coach form, proper head and neck position, proper breathing technique, and much more. Attract and retain more clients  This podcast episode is brought to you by ARX Do you struggle to attract and retain clients in your strength training studio? ARX machines use breakthrough motorized resistance and computer software to give your clients the perfect workout every time, so you can start to deliver great workouts and grow your business with confidence. Get $500 OFF by going to ARXFit.com/HIB and booking a call with the ARX sales team – Book Here For all of the show notes, links and resources - Click Here

I have the privilege of talking with Dr. Gregory Postma, MD, a laryngologist who's been around the world of head and neck and back again. Dr. Postma shares his experiences collaborating as a member of the interdisciplinary team, we discuss changes to our shared area of practice over the last few decades, and ways in which SLPs and laryngologist can continue to collaborate to provide the highest caliber of care for our patients. The post 233 – Laryngologists and SLPs: Head and Neck BFFs with Gregory Postma, MD appeared first on Swallow Your Pride Podcast.

I have the privilege of talking with Dr. Gregory Postma, MD, a laryngologist who's been around the world of head and neck and back again. Dr. Postma shares his experiences collaborating as a member of the interdisciplinary team, we discuss changes to our shared area of practice over the last few decades, and ways in which SLPs and laryngologist can continue to collaborate to provide the highest caliber of care for our patients. The post 233 – Laryngologists and SLPs: Head and Neck BFFs with Gregory Postma, MD appeared first on Swallow Your Pride Podcast.